Cat. No. | Product name | CAS No. |
DCC5519 |
Whz-04
Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor |
|
DCC5520 |
Win-35428
Dopamine reuptake inhibitor, also having some SERT affinity |
50370-56-4 |
DCC5521 |
Win-64338
B2 bradykinin receptor antagonist |
151039-63-3 |
DCC5522 |
Withangulatin A
Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2 |
120824-03-5 |
DCC5523 |
Wj35435
Novel dual inhibitor of histone deacetylase and topoisomerase I |
1620054-84-3 |
DCC5524 |
Wjd008
Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant |
1309087-83-9 |
DCC5525 |
Wms-1410
Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen |
|
DCC5526 |
Wms-2539
Potent uncompetitive NMDA receptor antagonist |
|
DCC5527 |
Wn1316
Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS) |
1356959-71-1 |
DCC5528 |
Wnk-in-3
Novel Allosteric WNK Kinase Inhibitor |
853298-47-2 |
DCC5529 |
Wnt/hh-in-1
Novel potent dual inhibitor of Wnt and hedgehog signalings, blocking porcupine and smoothened |
|
DCC5530 |
Wny0824
Novel dual BRD4 and PLK1 inhibitor (IC 50 values of 109 and 22 nM, respectively), showing strong antiproliferative activity against cancer cells |
|
DCC5531 |
Wo-459
Novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells |
1313195-84-4 |
DCC5532 |
Wp1193
Novel inhibitor of the JAK2/STAT3 pathway |
951693-87-1 |
DCC5533 |
Wp-871 Monohydrate
Main active metabolite of tazanolast, inhibiting dose-dependently compound 48/80-induced histamine release from rat peritoneal mast cells |
1184521-48-9 |
DCC5534 |
Wqe-134
Novel Dual Inhibitor of Nitric Oxide and Prostaglandin E2 Production |
|
DCC5535 |
Wr99210
Potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR) |
47326-86-3 |
DCC5536 |
Wrr-286
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.6 nM |
|
DCC5537 |
Wrr-391
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.2 nM |
|
DCC5538 |
wrr-483
Analog of K11777; Irriversible effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. |
1076089-14-9 |
DCC5539 |
Ws-47-js03
Novel potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays |
|
DCC5540 |
Ws-691
Novel highly potent and orally active ABCB1 modulator capable of overcoming MDR, stabilizing ABCB1 by directly binding to ABCB1, stimulating the activity of ABCB1 ATPase without inhibitory activity against CYP3A4, increasing the sensitivity of SW620/Ad300 |